Basic biology of adeno-associated virus (AAV) vectors used in gene therapy

Current Gene Therapy

Volumn 14, Issue 2, 2014, Pages 86-100

  Balakrishnan, Balaji ^a   Jayandharan, Giridhara R ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Adeno associated virus; Gene therapy; Integration; Serotype; Viral vectors

Indexed keywords

CYCLINE; DNA DIRECTED DNA POLYMERASE DELTA; EARLY ENDOSOME ANTIGEN 1; FUSED IN SARCOMA PROTEIN; INSULIN RECEPTOR SUBSTRATE; MINICHROMOSOME MAINTENANCE PROTEIN; PARVOVIRUS VECTOR; PHOSPHOLIPASE A2; PROTEIN VP1; PROTEOHEPARAN SULFATE; RAB11 PROTEIN; REPLICATION FACTOR C; UBIQUITIN PROTEIN LIGASE;

ARTICLE; BINDING SITE; CAP GENE; CELL MIGRATION; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; DNA END JOINING REPAIR; ENDOCYTOSIS; GENE; GENE EXPRESSION; GENE THERAPY; HUMAN; INVERTED TERMINAL REPEAT; LATENT PERIOD; LIFE CYCLE; MITOCHONDRION; NONHUMAN; OPEN READING FRAME; REP GENE; SEROTYPE; SIGNAL TRANSDUCTION; START CODON; UNFOLDED PROTEIN RESPONSE; VIRAL TROPISM; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS INFECTION; VIRUS REPLICATION; VIRUS UNCOATING; DEPENDOPARVOVIRUS; GENE TRANSFER; GENE VECTOR; GENETICS; HOST PATHOGEN INTERACTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROCEDURES;

CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DEPENDOVIRUS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HOST-PATHOGEN INTERACTIONS; HUMANS;

EID: 84904513609     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/1566523214666140302193709     Document Type: Article

References (189)

1. Atchison RW, Casto BC, Hammon WM. Adenovirus-Associated Defective Virus Particles. Science 1965; 149(3685):754-6.
2. Hoggan MD, Blacklow NR, Rowe WP. Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics. Proc Natl Acad Sci U S A. 1966 Jun; 55(6):1467-74.
3. Rose JA, Berns KI, Hoggan MD, Koczot FJ. Evidence for a singlestranded adenovirus-associated virus genome: formation of a DNA density hybrid on release of viral DNA. Proc Natl Acad Sci U S A 1969; 64(3):863-9.
4. Hermonat PL, Muzyczka N. Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci U S A 1984; 81(20):6466-70.
5. Wu Z, Yang H, Colosi P. Effect of genome size on AAV vector packaging. Mol Ther 2010; 18(1):80-6.
6. Bartel M, Schaffer D, Buning H. Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity. Front Microbiol 2011; 2:204.
7. Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 2013; 122(1):23-36.
8. Hareendran S, Balakrishnan B, Sen D, Kumar S, Srivastava A, Jayandharan GR. Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them. Rev Med Virol 2013; 23(6):399-413.
9. Berns KI, Pinkerton TC, Thomas GF, Hoggan MD. Detection of adeno-associated virus (AAV)-specific nucleotide sequences in DNA isolated from latently infected Detroit 6 cells. Virology 1975; 68(2):556-60.
10. Cheung AK, Hoggan MD, Hauswirth WW, Berns KI. Integration of the adeno-associated virus genome into cellular DNA in latently infected human Detroit 6 cells. J Virol 1980; 33(2):739-48.
11. Tan I, Ng CH, Lim L, Leung T. Phosphorylation of a novel myosin binding subunit of protein phosphatase 1 reveals a conserved mechanism in the regulation of actin cytoskeleton. J Biol Chem 2001; 276(24):21209-16.
12. Dutheil N, Shi F, Dupressoir T, Linden RM. Adeno-associated virus site-specifically integrates into a muscle-specific DNA region. Proc Natl Acad Sci U S A 2000; 97(9):4862-6.
13. Dutheil N, Yoon-Robarts M, Ward P, et al. Characterization of the mouse adeno-associated virus AAVS1 ortholog. J Virol 2004; 78(16):8917-21.
14. Henckaerts E, Dutheil N, Zeltner N, et al. Site-specific integration of adeno-associated virus involves partial duplication of the target locus. Proc Natl Acad Sci U S A 2009; 106(18):7571-6.
15. Henckaerts E, Linden RM. Adeno-associated virus: a key to the human genome? Future Virol 2010; 5(5):555-74.
16. Huser D, Gogol-Doring A, Lutter T, et al. Integration preferences of wildtype AAV-2 for consensus rep-binding sites at numerous loci in the human genome. PLoS Pathog 2010; 6(7):e1000985.
17. Mehrle S, Rohde V, Schlehofer JR. Evidence of chromosomal integration of AAV DNA in human testis tissue. Virus Genes 2004; 28(1):61-9.
18. Hernandez YJ, Wang J, Kearns WG, Loiler S, Poirier A, Flotte TR. Latent adeno-associated virus infection elicits humoral but not cellmediated immune responses in a nonhuman primate model. J Virol 1999; 73(10):8549-58.
19. McCarty DM, Young SM, Jr., Samulski RJ. Integration of adenoassociated virus (AAV) and recombinant AAV vectors. Annu Rev Genet 2004; 38:819-45.
20. Chang LS, Shi Y, Shenk T. Adeno-associated virus P5 promoter contains an adenovirus E1A-inducible element and a binding site for the major late transcription factor. J Virol 1989; 63(8):3479-88.
21. Shi Y, Seto E, Chang LS, Shenk T. Transcriptional repression by YY1, a human GLI-Kruppel-related protein, and relief of repression by adenovirus E1A protein. Cell 1991; 67(2):377-88.
22. Weitzman MD, Fisher KJ, Wilson JM. Recruitment of wild-type and recombinant adeno-associated virus into adenovirus replication centers. J Virol 1996; 70(3):1845-54.
23. Ward P, Dean FB, O'Donnell ME, Berns KI. Role of the adenovirus DNA-binding protein in in vitro adeno-associated virus DNA replication. J Virol 1998; 72(1):420-7.
24. Samulski RJ, Shenk T. Adenovirus E1B 55-Mr polypeptide facilitates timely cytoplasmic accumulation of adeno-associated virus mRNAs. J Virol 1988; 62(1):206-10.
25. Fisher KJ, Gao GP, Weitzman MD, DeMatteo R, Burda JF, Wilson JM. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol 1996; 70(1):520-32.
26. Nayak R, Pintel DJ. Adeno-associated viruses can induce phosphorylation of eIF2alpha via PKR activation, which can be overcome by helper adenovirus type 5 virus-associated RNA. J Virol 2007; 81(21):11908-16.
27. Weindler FW, Heilbronn R. A subset of herpes simplex virus replication genes provides helper functions for productive adenoassociated virus replication. J Virol 1991; 65(5):2476-83.
28. Stracker TH, Cassell GD, Ward P, et al. The Rep protein of adenoassociated virus type 2 interacts with single-stranded DNA-binding proteins that enhance viral replication. J Virol 2004; 78(1):441-53.
29. Alex M, Weger S, Mietzsch M, Slanina H, Cathomen T, Heilbronn R. DNA-binding activity of adeno-associated virus Rep is required for inverted terminal repeat-dependent complex formation with herpes simplex virus ICP8. J Virol 2012; 86(5):2859-63.
30. Geoffroy MC, Epstein AL, Toublanc E, Moullier P, Salvetti A. Herpes simplex virus type 1 ICP0 protein mediates activation of adeno-associated virus type 2 rep gene expression from a latent integrated form. J Virol 2004; 78(20):10977-86.
31. Saudan P, Vlach J, Beard P. Inhibition of S-phase progression by adeno-associated virus Rep78 protein is mediated by hypophosphorylated pRb. EMBO J 2000; 19(16):4351-61.
32. Young SM Jr, McCarty DM, Degtyareva N, Samulski RJ. Roles of adeno-associated virus Rep protein and human chromosome 19 in site-specific recombination. J Virol 2000; 74(9):3953-66.
33. Berthet C, Raj K, Saudan P, Beard P. How adeno-associated virus Rep78 protein arrests cells completely in S phase. Proc Natl Acad Sci U S A 2005; 102(38):13634-9.
34. Zarate-Perez F, Mansilla-Soto J, Bardelli M, et al. Oligomeric properties of adeno-associated virus Rep68 reflect its multifunctionality. J Virol 2013; 87(2):1232-41.
35. James JA, Escalante CR, Yoon-Robarts M, Edwards TA, Linden RM, Aggarwal AK. Crystal structure of the SF3 helicase from adeno-associated virus type 2. Structure 2003; 11(8):1025-35.
36. Yoon-Robarts M, Blouin AG, Bleker S, et al. Residues within the B' motif are critical for DNA binding by the superfamily 3 helicase Rep40 of adeno-associated virus type 2. J Biol Chem 2004; 279(48):50472-81.
37. King JA, Dubielzig R, Grimm D, Kleinschmidt JA. DNA helicasemediated packaging of adeno-associated virus type 2 genomes into preformed capsids. EMBO J 2001; 20(12):3282-91.
38. Collaco RF, Kalman-Maltese V, Smith AD, Dignam JD, Trempe JP. A biochemical characterization of the adeno-associated virus Rep40 helicase. J Biol Chem 2003; 278(36):34011-7.
39. Chapman MS, M. Agbandje-McKenna., editor. Atomic structure of viral particles: Edward Arnold, Ltd.; 2006.
40. Rose JA, Maizel JV Jr, Inman JK, Shatkin AJ. Structural proteins of adenovirus-associated viruses. J Virol 1971; 8(5):766-70.
41. Johnson FB, Ozer HL, Hoggan MD. Structural proteins of adenovirus-associated virus type 3. J Virol 1971; 8(6):860-3.
42. Sonntag F, Bleker S, Leuchs B, Fischer R, Kleinschmidt JA. Adeno-associated virus type 2 capsids with externalized VP1/VP2 trafficking domains are generated prior to passage through the cytoplasm and are maintained until uncoating occurs in the nucleus. J Virol 2006; 80(22):11040-54.
43. Girod A, Wobus CE, Zadori Z, et al. The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J Gen Virol 2002; 83(Pt 5):973-8.
44. Canaan S, Zadori Z, Ghomashchi F, et al. Interfacial enzymology of parvovirus phospholipases A2. J Biol Chem 2004; 279(15):14502-8.
45. Bleker S, Sonntag F, Kleinschmidt JA. Mutational analysis of narrow pores at the fivefold symmetry axes of adeno-associated virus type 2 capsids reveals a dual role in genome packaging and activation of phospholipase A2 activity. J Virol 2005; 79(4):2528-40.
46. Johnson JS, Li C, DiPrimio N, Weinberg MS, McCown TJ, Samulski RJ. Mutagenesis of adeno-associated virus type 2 capsid protein VP1 uncovers new roles for basic amino acids in trafficking and cell-specific transduction. J Virol 2010; 84(17):8888-902.
47. Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl Acad Sci U S A 2010; 107(22):10220-5.
48. Gao G, Vandenberghe LH, Alvira MR, et al. Clades of Adenoassociated viruses are widely disseminated in human tissues. J Virol 2004; 78(12):6381-8.
49. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A 2002; 99(18):11854-9.
50. Xie Q, Bu W, Bhatia S, et al. The atomic structure of adenoassociated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci U S A 2002; 99(16):10405-10.
51. Parks WP, Melnick JL, Rongey R, Mayor HD. Physical assay and growth cycle studies of a defective adeno-satellite virus. J Virol 1967; 1(1):171-80.
52. Govindasamy L, Padron E, McKenna R, et al. Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. J Virol 2006; 80(23):11556-70.
53. Bantel-Schaal U, zur Hausen H. Characterization of the DNA of a defective human parvovirus isolated from a genital site. Virology 1984; 134(1):52-63.
54. Rutledge EA, Halbert CL, Russell DW. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J Virol 1998; 72(1):309-19.
55. Ng R, Govindasamy L, Gurda BL, et al. Structural characterization of the dual glycan binding adeno-associated virus serotype 6. J Virol 2010; 84(24):12945-57.
56. Nam HJ, Lane MD, Padron E, et al. Structure of adeno-associated virus serotype 8, a gene therapy vector. J Virol 2007; 81(22):12260-71.
57. DiMattia MA, Nam HJ, van Vliet K, et al. Structural insight into the unique properties of adeno-associated virus serotype 9. J Virol 2012; 86(12):6947-58.
58. Mori S, Wang L, Takeuchi T, Kanda T. Two novel adenoassociated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein. Virology 2004; 330(2):375-83.
59. Schmidt M, Voutetakis A, Afione S, Zheng C, Mandikian D, Chiorini JA. Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid-and heparan sulfate proteoglycanindependent transduction activity. J Virol 2008; 82(3):1399-406.
60. Halbert CL, Rutledge EA, Allen JM, Russell DW, Miller AD. Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J Virol 2000; 74(3):1524-32.
61. Gregorevic P, Blankinship MJ, Allen JM, et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 2004; 10(8):828-34.
62. Rabinowitz JE, Rolling F, Li C, et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002; 76(2):791-801.
63. Grimm D, Pandey K, Nakai H, Storm TA, Kay MA. Liver transduction with recombinant adeno-associated virus is primarily restricted by capsid serotype not vector genotype. J Virol 2006; 80(1):426-39.
64. Yang GS, Schmidt M, Yan Z, et al. Virus-mediated transduction of murine retina with adeno-associated virus: effects of viral capsid and genome size. J Virol 2002; 76(15):7651-60.
65. Acland GM, Aguirre GD, Ray J, et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 2001; 28(1):92-5.
66. Bennett J, Maguire AM, Cideciyan AV, et al. Stable transgene expression in rod photoreceptors after recombinant adenoassociated virus-mediated gene transfer to monkey retina. Proc Natl Acad Sci U S A 1999; 96(17):9920-5.
67. Weber M, Rabinowitz J, Provost N, et al. Recombinant adenoassociated virus serotype 4 mediates unique and exclusive longterm transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate after subretinal delivery. Mol Ther 2003; 7(6):774-81.
68. Lotery AJ, Yang GS, Mullins RF, et al. Adeno-associated virus type 5: transduction efficiency and cell-type specificity in the primate retina. Hum Gene Ther 2003; 14(17):1663-71.
69. Griffey MA, Wozniak D, Wong M, et al. CNS-directed AAV2-mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis. Mol Ther 2006; 13(3):538-47.
70. Burger C, Gorbatyuk OS, Velardo MJ, et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 2004; 10(2):302-17.
71. During MJ, Samulski RJ, Elsworth JD, et al. In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Ther 1998; 5(6):820-7.
72. Alisky JM, Hughes SM, Sauter SL, et al. Transduction of murine cerebellar neurons with recombinant FIV and AAV5 vectors. Neuroreport 2000; 11(12):2669-73.
73. Colle MA, Piguet F, Bertrand L, et al. Efficient intracerebral delivery of AAV5 vector encoding human ARSA in non-human primate. Hum Mol Genet 2010; 19(1):147-58.
74. Broekman ML, Comer LA, Hyman BT, Sena-Esteves M. Adenoassociated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or-2 serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience 2006; 138(2):501-10.
75. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009; 27(1):59-65.
76. Xue YQ, Ma BF, Zhao LR, et al. AAV9-mediated erythropoietin gene delivery into the brain protects nigral dopaminergic neurons in a rat model of Parkinson's disease. Gene Ther 2010; 17(1):83-94.
77. Duque S, Joussemet B, Riviere C, et al. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 2009; 17(7):1187-96.
78. De BP, Heguy A, Hackett NR, et al. High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses. Mol Ther 2006; 13(1):67-76.
79. Du L, Kido M, Lee DV, et al. Differential myocardial gene delivery by recombinant serotype-specific adeno-associated viral vectors. Mol Ther 2004; 10(3):604-8.
80. Pacak CA, Mah CS, Thattaliyath BD, et al. Recombinant adenoassociated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res 2006; 99(4):e3-9.
81. Li J, Wang D, Qian S, Chen Z, Zhu T, Xiao X. Efficient and longterm intracardiac gene transfer in delta-sarcoglycan-deficiency hamster by adeno-associated virus-2 vectors. Gene Ther 2003; 10(21):1807-13.
82. Towne C, Raoul C, Schneider BL, Aebischer P. Systemic AAV6 delivery mediating RNA interference against SOD1: neuromuscular transduction does not alter disease progression in fALS mice. Mol Ther 2008; 16(6):1018-25.
83. Wang Z, Zhu T, Qiao C, et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 2005; 23(3):321-8.
84. Paneda A, Vanrell L, Mauleon I, et al. Effect of adeno-associated virus serotype and genomic structure on liver transduction and biodistribution in mice of both genders. Hum Gene Ther 2009; 20(8):908-17.
85. Byrne MJ, Power JM, Preovolos A, Mariani JA, Hajjar RJ, Kaye DM. Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Ther 2008; 15(23):1550-7.
86. Ponnazhagan S, Mukherjee P, Yoder MC, et al. Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice. Gene 1997; 190(1):203-10.
87. Mount JD, Herzog RW, Tillson DM, et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood 2002; 99(8):2670-6.
88. Kitajima K, Marchadier DH, Burstein H, Rader DJ. Persistent liver expression of murine apoA-l using vectors based on adenoassociated viral vectors serotypes 5 and 1. Atherosclerosis 2006; 186(1):65-73.
89. Nathwani AC, Gray JT, Ng CY, et al. Self-complementary adenoassociated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood 2006; 107(7):2653-61.
90. Jiang H, Lillicrap D, Patarroyo-White S, et al. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood 2006; 108(1):107-15.
91. Moscioni D, Morizono H, McCarter RJ, et al. Long-term correction of ammonia metabolism and prolonged survival in ornithine transcarbamylase-deficient mice following liver-directed treatment with adeno-associated viral vectors. Mol Ther 2006; 14(1):25-33.
92. Sarkar R, Mucci M, Addya S, et al. Long-term efficacy of adenoassociated virus serotypes 8 and 9 in hemophilia a dogs and mice. Hum Gene Ther 2006; 17(4):427-39.
93. Inagaki K, Fuess S, Storm TA, et al. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 2006; 14(1):45-53.
94. Yan Z, Lei-Butters DC, Liu X, et al. Unique biologic properties of recombinant AAV1 transduction in polarized human airway epithelia. J Biol Chem 2006; 281(40):29684-92.
95. Flotte TR, Fischer AC, Goetzmann J, et al. Dual reporter comparative indexing of rAAV pseudotyped vectors in chimpanzee airway. Mol Ther 2010; 18(3):594-600.
96. Snyder RO, Miao CH, Patijn GA, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997; 16(3):270-6.
97. Gao GP, Lu Y, Sun X, et al. High-level transgene expression in nonhuman primate liver with novel adeno-associated virus serotypes containing self-complementary genomes. J Virol 2006; 80(12):6192-4.
98. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 2008; 16(6):1073-80.
99. Asokan A, Conway JC, Phillips JL, et al. Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat Biotechnol 2010; 28(1):79-82.
100. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998; 72(2):1438-45.
101. Chen CL, Jensen RL, Schnepp BC, et al. Molecular characterization of adeno-associated viruses infecting children. J Virol 2005; 79(23):14781-92.
102. Kern A, Schmidt K, Leder C, et al. Identification of a heparinbinding motif on adeno-associated virus type 2 capsids. J Virol 2003; 77(20):11072-81.
103. Opie SR, Warrington KH, Jr., Agbandje-McKenna M, Zolotukhin S, Muzyczka N. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J Virol 2003; 77(12):6995-7006.
104. Levy HC, Bowman VD, Govindasamy L, et al. Heparin binding induces conformational changes in Adeno-associated virus serotype 2. J Struct Biol 2009; 165(3):146-56.
105. O'Donnell J, Taylor KA, Chapman MS. Adeno-associated virus-2 and its primary cellular receptor--Cryo-EM structure of a heparin complex. Virology 2009; 385(2):434-43.
106. Bartlett JS, Wilcher R, Samulski RJ. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J Virol 2000; 74(6):2777-85.
107. Duan D, Li Q, Kao AW, Yue Y, Pessin JE, Engelhardt JF. Dynamin is required for recombinant adeno-associated virus type 2 infection. J Virol 1999; 73(12):10371-6.
108. Mercer J, Helenius A. Virus entry by macropinocytosis. Nat Cell Biol 2009; 11(5):510-20.
109. Sanlioglu S, Benson PK, Yang J, Atkinson EM, Reynolds T, Engelhardt JF. Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation. J Virol 2000; 74(19):9184-96.
110. Clague MJ. Molecular aspects of the endocytic pathway. Biochem J 1998; 336 (Pt 2):271-82.
111. Nonnenmacher M, Weber T. Adeno-associated virus 2 infection requires endocytosis through the CLIC/GEEC pathway. Cell Host Microbe 2011; 10(6):563-76.
112. Joo KI, Fang Y, Liu Y, et al. Enhanced real-time monitoring of adeno-associated virus trafficking by virus-quantum dot conjugates. ACS Nano 2014; 5(5):3523-35.
113. Hansen J, Qing K, Kwon HJ, Mah C, Srivastava A. Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts. J Virol 2000; 74(2):992-6.
114. Ding W, Zhang LN, Yeaman C, Engelhardt JF. rAAV2 traffics through both the late and the recycling endosomes in a dosedependent fashion. Mol Ther 2006; 13(4):671-82.
115. Ding W, Zhang L, Yan Z, Engelhardt JF. Intracellular trafficking of adeno-associated viral vectors. Gene Ther 2005; 12(11):873-80.
116. Grieger JC, Snowdy S, Samulski RJ. Separate basic region motifs within the adeno-associated virus capsid proteins are essential for infectivity and assembly. J Virol 2006; 80(11):5199-210.
117. Johnson JS, Gentzsch M, Zhang L, et al. AAV exploits subcellular stress associated with inflammation, endoplasmic reticulum expansion, and misfolded proteins in models of cystic fibrosis. PLoS Pathog 2011; 7(5):e1002053.
118. Salganik M, Venkatakrishnan B, Bennett A, et al. Evidence for pHdependent protease activity in the adeno-associated virus capsid. J Virol 2012; 86(21):11877-85.
119. Jackson LP, Lewis M, Kent HM, et al. Molecular basis for recognition of dilysine trafficking motifs by COPI. Dev Cell. 2012; 23(6):1255-62.
120. Balakrishnan B, Sen D, Hareendran S, et al. Activation of the cellular unfolded protein response by recombinant adeno-associated virus vectors. PLoS One 2013; 8(1):e53845.
121. Xiao PJ, Samulski RJ. Cytoplasmic trafficking, endosomal escape, and perinuclear accumulation of adeno-associated virus type 2 particles are facilitated by microtubule network. J Virol 2012; 86(19):10462-73.
122. Lux K, Goerlitz N, Schlemminger S, et al. Green fluorescent protein-tagged adeno-associated virus particles allow the study of cytosolic and nuclear trafficking. J Virol 2005; 79(18):11776-87.
123. Xiao W, Warrington KH, Jr., Hearing P, Hughes J, Muzyczka N. Adenovirus-facilitated nuclear translocation of adeno-associated virus type 2. J Virol 2002; 76(22):11505-17.
124. Johnson JS, Samulski RJ. Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus. J Virol 2009; 83(6):2632-44.
125. Owens RA, Weitzman MD, Kyostio SR, Carter BJ. Identification of a DNA-binding domain in the amino terminus of adenoassociated virus Rep proteins. J Virol 1993; 67(2):997-1005.
126. Brister JR, Muzyczka N. Mechanism of Rep-mediated adenoassociated virus origin nicking. J Virol 2000; 74(17):7762-71.
127. Chiorini JA, Wiener SM, Owens RA, Kyostio SR, Kotin RM, Safer B. Sequence requirements for stable binding and function of Rep68 on the adeno-associated virus type 2 inverted terminal repeats. J Virol 1994; 68(11):7448-57.
128. McCarty DM, Pereira DJ, Zolotukhin I, Zhou X, Ryan JH, Muzyczka N. Identification of linear DNA sequences that specifically bind the adeno-associated virus Rep protein. J Virol 1994; 68(8):4988-97.
129. Nash K, Chen W, Muzyczka N. Complete in vitro reconstitution of adeno-associated virus DNA replication requires the minichromosome maintenance complex proteins. J Virol 2008; 82(3):1458-64.
130. Nash K, Chen W, Salganik M, Muzyczka N. Identification of cellular proteins that interact with the adeno-associated virus rep protein. J Virol 2009; 83(1):454-69.
131. Pereira DJ, McCarty DM, Muzyczka N. The adeno-associated virus (AAV) Rep protein acts as both a repressor and an activator to regulate AAV transcription during a productive infection. J Virol 1997; 71(2):1079-88.
132. Lackner DF, Muzyczka N. Studies of the mechanism of transactivation of the adeno-associated virus p19 promoter by Rep protein. J Virol 2002; 76(16):8225-35.
133. Kyostio SR, Wonderling RS, Owens RA. Negative regulation of the adeno-associated virus (AAV) P5 promoter involves both the P5 rep binding site and the consensus ATP-binding motif of the AAV Rep68 protein. J Virol 1995; 69(11):6787-96.
134. Murphy M, Gomos-Klein J, Stankic M, Falck-Pedersen E. Adenoassociated virus type 2 p5 promoter: a rep-regulated DNA switch element functioning in transcription, replication, and site-specific integration. J Virol 2007; 81(8):3721-30.
135. Tratschin JD, Miller IL, Carter BJ. Genetic analysis of adenoassociated virus: properties of deletion mutants constructed in vitro and evidence for an adeno-associated virus replication function. J Virol 1984; 51(3):611-9.
136. Yu H, Koilkonda RD, Chou TH, et al. Gene delivery to mitochondria by targeting modified adenoassociated virus suppresses Leber's hereditary optic neuropathy in a mouse model. Proc Natl Acad Sci U S A 2012; 109(20):E1238-47.
137. Kaeppel C, Beattie SG, Fronza R, et al. A largely random AAV integration profile after LPLD gene therapy. Nat Med 2013; 19(7):889-91.
138. Weitzman MD, Kyostio SR, Kotin RM, Owens RA. Adenoassociated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. Proc Natl Acad Sci U S A 1994; 91(13):5808-12.
139. Balague C, Kalla M, Zhang WW. Adeno-associated virus Rep78 protein and terminal repeats enhance integration of DNA sequences into the cellular genome. J Virol 1997; 71(4):3299-306.
140. Linden RM, Ward P, Giraud C, Winocour E, Berns KI. Sitespecific integration by adeno-associated virus. Proc Natl Acad Sci U S A 1996; 93(21):11288-94.
141. Huttner NA, Girod A, Schnittger S, Schoch C, Hallek M, Buning H. Analysis of site-specific transgene integration following cotransduction with recombinant adeno-associated virus and a rep encodingplasmid. J Gene Med 2003; 5(2):120-9.
142. Surosky RT, Urabe M, Godwin SG, et al. Adeno-associated virus Rep proteins target DNA sequences to a unique locus in the human genome. J Virol 1997; 71(10):7951-9.
143. Lamartina S, Roscilli G, Rinaudo D, Delmastro P, Toniatti C. Lipofection of purified adeno-associated virus Rep68 protein: toward a chromosome-targeting nonviral particle. J Virol 1998; 72(9):7653-8.
144. Rinaudo D, Lamartina S, Roscilli G, Ciliberto G, Toniatti C. Conditional site-specific integration into human chromosome 19 by using a ligand-dependent chimeric adeno-associated virus/Rep protein. J Virol 2000; 74(1):281-94.
145. Howden SE, Voullaire L, Vadolas J. The transient expression of mRNA coding for Rep protein from AAV facilitates targeted plasmid integration. J Gene Med 2008; 10(1):42-50.
146. Recchia A, Mavilio F. Site-specific integration by the adenoassociated virus rep protein. Curr Gene Ther 2011; 11(5):399-405.
147. Daya S, Cortez N, Berns KI. Adeno-associated virus site-specific integration is mediated by proteins of the nonhomologous endjoining pathway. J Virol 2009; 83(22):11655-64.
148. Inagaki K, Ma C, Storm TA, Kay MA, Nakai H. The role of DNAPKcs and artemis in opening viral DNA hairpin termini in various tissues in mice. J Virol 2007; 81(20):11304-21.
149. Gantz JA, Palpant NJ, Welikson RE, Hauschka SD, Murry CE, Laflamme MA. Targeted genomic integration of a selectable floxed dual fluorescence reporter in human embryonic stem cells. PLoS One 2012; 7(10):e46971.
150. Chang CJ, Bouhassira EE. Zinc-finger nuclease-mediated correction of alpha-thalassemia in iPS cells. Blood 2012; 120(19):3906-14.
151. Handel EM, Cathomen T. Zinc-finger nuclease based genome surgery: it's all about specificity. Curr Gene Ther 2011; 11(1):28-37.
152. Scharenberg AM, Duchateau P, Smith J. Genome engineering with TAL-effector nucleases and alternative modular nuclease technologies. Curr Gene Ther 2013; 13(4):291-303.
153. Smith RH. Adeno-associated virus integration: virus versus vector. Gene Ther 2008; 15(11):817-22.
154. McCarty DM. Self-complementary AAV vectors; advances and applications. Mol Ther 2008; 16(10):1648-56.
155. Asokan A, Schaffer DV, Samulski RJ. The AAV vector toolkit: poised at the clinical crossroads. Mol Ther 2012; 20(4):699-708.
156. Stroes ES, Nierman MC, Meulenberg JJ, et al. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol 2008; 28(12):2303-4.
157. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008; 358(21):2231-9.
158. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008; 358(21):2240-8.
159. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12(3):342-7.
160. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirusassociated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365(25):2357-65.
161. Kotin RM. Large-scale recombinant adeno-associated virus production. Hum Mol Genet 2011; 20(R1):R2-6.
162. Galibert L, Merten OW. Latest developments in the large-scale production of adeno-associated virus vectors in insect cells toward the treatment of neuromuscular diseases. J Invertebr Pathol 2011; 107 Suppl:S80-93.
163. Chadeuf G, Favre D, Tessier J, et al. Efficient recombinant adenoassociated virus production by a stable rep-cap HeLa cell line correlates with adenovirus-induced amplification of the integrated repcap genome. J Gene Med 2000; 2(4):260-8.
164. Chadeuf G, Salvetti A. Stable producer cell lines for adenoassociated virus (AAV) assembly. Cold Spring Harb Protoc 2010(10):pdb prot5496.
165. Goncalves MA, van der Velde I, Janssen JM, et al. Efficient generation and amplification of high-capacity adeno-associated virus/ adenovirus hybrid vectors. J Virol 2002; 76(21):10734-44.
166. Flotte T, Carter B, Conrad C, et al. A phase I study of an adenoassociated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum Gene Ther 1996; 7(9):1145-59.
167. Di Paolo NC, van Rooijen N, Shayakhmetov DM. Redundant and synergistic mechanisms control the sequestration of blood-born adenovirus in the liver. Mol Ther 2009; 17(4):675-84.
168. Schipper ML, Iyer G, Koh AL, et al. Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small 2009; 5(1):126-34.
169. Bowles DE, McPhee SW, Li C, et al. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther 2011; 20(2):443-55.
170. Petrs-Silva H, Linden R. Advances in recombinant adenoassociated viral vectors for gene delivery. Curr Gene Ther 2013; 13(5):335-45.
171. Bartel M, Schaffer D, Buning H. Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity. Front Microbiol 2011; 2:204.
172. Yan Z, Zak R, Luxton GW, Ritchie TC, Bantel-Schaal U, Engelhardt JF. Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. J Virol 2002; 76(5):2043-53.
173. Jayandharan GR, Zhong L, Li B, Kachniarz B, Srivastava A. Strategies for improving the transduction efficiency of singlestranded adeno-associated virus vectors in vitro and in vivo. Gene Ther 2008; 15(18):1287-93.
174. Zhong L, Zhao W, Wu J, et al. A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis. Mol Ther 2007; 15(7):1323-30.
175. Monahan PE, Lothrop CD, Sun J, et al. Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application. Mol Ther 2010; 18(11):1907-16.
176. Zhong L, Li B, Mah CS, et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A 2008; 105(22):7827-32.
177. Kauss MA, Smith LJ, Zhong L, Srivastava A, Wong KK, Jr., Chatterjee S. Enhanced long-term transduction and multilineage engraftment of human hematopoietic stem cells transduced with tyrosine-modified recombinant adeno-associated virus serotype 2. Hum Gene Ther 2010; 21(9):1129-36.
178. Gabriel N, Hareendran S, Sen D, et al. Bioengineering of AAV2 capsid at specific serine, threonine, or lysine residues improves its transduction efficiency in vitro and in vivo. Hum Gene Ther Methods 2013; 24(2):80-93.
179. Sen D, Balakrishnan B, Gabriel N, et al. Improved adenoassociated virus (AAV) serotype 1 and 5 vectors for gene therapy. Sci Rep 2013; 3:1832.
180. Sen D, Gadkari RA, Sudha G, et al. Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo. Hum Gene Ther Methods 2013; 24(2):104-16.
181. Wang Z, Ma HI, Li J, Sun L, Zhang J, Xiao X. Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther 2003; 10(26):2105-11.
182. Kanazawa T, Urabe M, Mizukami H, et al. Gamma-rays enhance rAAV-mediated transgene expression and cytocidal effect of AAVHSVtk/ ganciclovir on cancer cells. Cancer Gene Ther 2001; 8(2):99-106.
183. Ferrari FK, Samulski T, Shenk T, Samulski RJ. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 1996; 70(5):3227-34.
184. McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 2001; 8(16):1248-54.
185. Wu J, Zhao W, Zhong L, et al. Self-complementary recombinant adeno-associated viral vectors: packaging capacity and the role of rep proteins in vector purity. Hum Gene Ther 2007; 18(2):171-82.
186. Wu Z, Sun J, Zhang T, et al. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol Ther 2008; 16(2):280-9.
187. Yan Z, Zhang Y, Duan D, Engelhardt JF. Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc Natl Acad Sci U S A 2000; 97(12):6716-21.
188. Ghosh A, Yue Y, Duan D. Viral serotype and the transgene sequence influence overlapping adeno-associated viral (AAV) vectormediated gene transfer in skeletal muscle. J Gene Med 2006; 8(3):298-305.
189. Vasileva A, Jessberger R. Precise hit: adeno-associated virus in gene targeting. Nat Rev Microbiol 2005; 3(11):837-47.